LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .

Thrombospondin-1 (TSP-1)-derived CD36 binding motif is a bioactive peptide cyclized by a disulfide bond, critical for TSP-1-CD36 interaction. Involved in cancer metastasis, tumor adhesion, and angiogenesis, this matrix-bound glycoprotein-origin peptide competitively inhibits platelet aggregation and tumor metastasis.

SLLK is a control peptide for LSKL.

LSKL, INhibitor of Thrombospondin (TSP-1) trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64709.

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA, a latency-associated protein (LAP)-TGFβ derived tetrapeptide, is a competitive antagonist of TGF-β1.

SLLK, Control Peptide for TSP1 Inhibitor acetate is a control peptide for LSKL.

Properdistatin, a peptide originating from the thrombospondin 1 (TSP-1) domain of properdin, exhibits angiogenesis inhibition and vascular function enhancement capabilities, showing promise for melanoma research [1].

Thrombospondin-1 (1016-1023) (human, bovine, mouse) is part of Thrombospondin-1 (TSP-1), a peptide with CD47 agonism.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

KRFK, a peptide originating from TSP-1, activates TGF-β and facilitates TGF-β-mediated signaling pathways, independently of thrombospondin (TSP) receptors like CD47 and CD36. This property makes KRFK a potential research tool for chronic ocular surface inflammatory disorders [1].

KRFK TFA, a TSP-1-derived peptide, activates TGF-β and enhances its associated signaling pathways independently of thrombospondin (TSP) receptors like CD47 and CD36. This compound has potential applications in research on chronic ocular surface inflammatory disorders [1].

ABT-510 is synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8).